Eli Lilly Says Sued Four U.S. Compounding Pharmacies For Selling Products Claiming To Contain Main Ingredient In Diabetes Drug Mounjaro For Weight Loss; Sued Six U.s. Medical Spas And Wellness Centers For Selling Products Advertised As Mounjaro
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has sued four U.S. compounding pharmacies for selling products claiming to contain the main ingredient in its diabetes drug Mounjaro for weight loss. The company has also sued six U.S. medical spas and wellness centers for selling products advertised as Mounjaro.
September 19, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eli Lilly's legal action against pharmacies and wellness centers could potentially impact its reputation and sales of its diabetes drug Mounjaro.
Eli Lilly's legal action is directly related to its product Mounjaro. The outcome of these lawsuits could potentially impact the company's reputation and the sales of Mounjaro. However, it's uncertain how this will affect the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100